Abbvie Inc.

Abbott Laboratories Corporation

Abbvie Bahamas Limited

Mark A Matulenko

Tammie K Jinkerson

David A DeGoey

Ryan G Keddy

Charles W Hutchins

Warren M Kati

Pamela L Donner

John T Randolph

Allan C Krueger

Kevin R Woller

Sachin V Patel

Christopher E Motter

Lissa T Nelson

John K Pratt

Rolf Wagner

Todd Warren Rockway

Dachun Liu

David A Betebenner

Douglas K Hutchinson

Clarence J Maring

Charles A Flentge

Michael D Tufano

Yi Gao

Kathy A Sarris

Seble H Wagaw

Wenke Li

Mary E Bellizzi

Daniel D Caspi

William A Carroll

Jean C Califano

Philip R Kym

Michael E Kort

Jerome F Daanen

John R Koenig

Meena V Patel

Marc J Scanio

Eric A Voight

Marlon D Cowart

Valentino J Stella

Arthur Gomtsyan

Bo Liu

Derek W Nelson

Peter T Mayer

Geoff G Zhang

Andrew Bogdan

Vincent S Chan

Yanbin Lao

Xiaochun Lou

Brian D Wakefield

Ye Huang

Hillary M Peltier

Jean-Christophe C Califano

Sean E Mackey

Zhi Wang

David A Degoey

Russell C Klix

Brian P Enright

James Patrick Stambuli

Christopher P Miller

Alexander D Huters

Scott W Krabbe

Benoit Cardinal-David

Kathy Sarris

Clara I Villamil

Xueqing Wang

Michael J Dart

Teodozyj Kolasa

Anil Vasudevan

Andrew O Stewart

Rodger F Henry

Jennifer M Frost

William H Bunnelle

Robert G Schmidt

Pramila A Bhatia

Tami J Pilot-Matias

Lei Shi

Brian S Brown

Henry Q Zhang

Kathleen Mortell

Zhiren Xia

Bruce Clapham

Phil B Cox

Preethi Krishnan

Todd N Soltwedel

Raimundo Ho

Neeta C Mistry

Steve Latshaw

Kassibla E Dempah

Ahmed A Hakeem

James Stambuli

Thomas J Reisch

Teresa (lok-Chan) Ng

Sachel V Patel

Sebel H Wagaw

The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.

Carbidopa and L-dopa prodrugs and methods of use

Compounds effective in inhibiting replication of Hepatitis C virus ('HCV') are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Anti-viral compounds

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein R, R, and Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

6-heteroaryloxy- or 6-aryloxy-quinoline-2-carboxamides and method of use

Compounds of formula (I) and pharmaceutically acceptable salts, esters, amides, or radiolabelled forms thereof, wherein A, Rand Rare as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by voltage-gated sodium channels, e.g., Na1.7 and/or Na1.8. Methods for making the compounds are disclosed. Also disclosed are pharmaceutical compositions of compounds of formula (I), and methods for using such compounds and compositions.

Indazole ureas and method of use

Disclosed herein are modulators of TRPV3 of formula (I) wherein X, X, R, R, R, and n are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.

TRPV3 modulators

Growing community of inventors

Libertyville, IL, United States of America

Mark A Matulenko